Department of Bioinformatics and Statistics, Graduate School of Korea National Open University, 86 Daehak-ro, Jongro-gu, Seoul, Republic of Korea.
Department of Acupuncture & Moxibustion Medicine, College of Korean Medicine, Gachon University 1342 Seongnamdae-ro, Sujeong-gu, Seongnam, Republic of Korea.
Medicine (Baltimore). 2022 Feb 11;101(6):e28819. doi: 10.1097/MD.0000000000028819.
Rheumatoid arthritis (RA) is a chronic, inflammatory, and painful joint disease. The aim of this review is to systematically evaluate the efficacy and safety of oral administration East Asian herbal medicine monotherapy for inflammatory pain of RA, and to explore core herb material information based on collected data.
A comprehensive literature search will be conducted in 11 electronic databases including PubMed, Cochrane Library, Cumulative Index to Nursing & Allied Health Literature, Excerpta Medica database, Korean Studies Information Service System, Research Information Service System Oriental Medicine Advanced Searching Integrated System, Korea Citation Index, Chinese National Knowledge Infrastructure Database, Wanfang data, citation information by NII for randomized controlled trials from their inception until October 13, 2021. Statistical analysis will be performed in the software R version 4.1.1. and R studio program using the default settings of the "meta" and "metafor" package. When heterogeneity in studies is detected, the cause will be identified through subgroup analysis. Methodological quality will be assessed independently using the revised tool for risk of bias in randomized trials (Rob 2.0).
This study will provide more comprehensive and specific evidence of East Asian herbal medicine monotherapy for RA pain management.
Based on the results of this review, it is expected that the efficacy and safety of East Asian herbal medicine for inflammatory pain of RA may be confirmed. In addition, it will be possible to derivation of a core herb material information related to this research topic through additional data mining.
There are no ethical issues as there are no primary data collected by directly recruiting subjects. The results of this review will be reported in a peer-reviewed scientific journal.
CRD42021273643.
类风湿性关节炎（RA）是一种慢性、炎症性和疼痛性关节疾病。本综述的目的是系统评估口服东亚草药单药治疗 RA 炎症性疼痛的疗效和安全性，并基于收集的数据探索核心草药材料信息。
将在 11 个电子数据库中进行全面的文献检索，包括 PubMed、Cochrane 图书馆、护理与联合健康文献累积索引、Excerpta Medica 数据库、韩国研究信息服务系统、研究信息服务系统东方医学高级搜索综合系统、韩国引文索引、中国国家知识基础设施数据库、万方数据、NII 引文信息，检索自试验开始至 2021 年 10 月 13 日的随机对照试验。统计分析将在 R 版本 4.1.1 和 R studio 程序中使用“meta”和“metafor”包的默认设置进行。当研究中存在异质性时，将通过亚组分析确定原因。将使用修订后的随机试验偏倚风险工具（Rob 2.0）独立评估方法学质量。
本研究将提供更全面和具体的东亚草药单药治疗 RA 疼痛管理的证据。
基于本综述的结果，预计东亚草药治疗 RA 炎症性疼痛的疗效和安全性可能得到证实。此外，通过额外的数据挖掘，有可能得出与这一研究主题相关的核心草药材料信息。
由于没有通过直接招募受试者收集原始数据，因此不存在伦理问题。本综述的结果将在同行评议的科学期刊上报告。
PROSPERO 注册号：CRD42021273643。
